Jim Cramer Says He Does Not Want Novo Nordisk Due to Tariffs

Novo Nordisk A/S (NYSE:NVO) is one of the stocks that Jim Cramer shed light on. A caller asked about the stock’s status, and Cramer replied:

“I want you to know I don’t want Novo Nordisk… and the reason that is because if there’s going to be talk about tariffs on foreign drugs versus Eli Lilly, Novo is going to have an even less of an edge on this thing. So I say Novo, we don’t need the bottom finish. It’s not for me.”

Novo Nordisk (NYSE:NVO) is engaged in the research, development, manufacturing, and distribution of pharmaceutical products. It is worth noting that when a caller asked Cramer if he thinks the stock is a buy in April, he said:

“I do…. It got low enough. When it hit 3.6% yield, it was low enough. Apparently, they’re doing exactly what President Trump wants. I am a buyer at this point in Novo Nordisk, though of course I do like Eli Lilly more, but this stock has come down enough.”

While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.